Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794662

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794662

Prion Disease Treatment

PUBLISHED:
PAGES: 268 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Prion Disease Treatment Market to Reach US$5.7 Billion by 2030

The global market for Prion Disease Treatment estimated at US$4.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Human Treatment, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Animal Treatment segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.4% CAGR

The Prion Disease Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Prion Disease Treatment Market - Key Trends & Drivers Summarized

Why Is the Prion Disease Treatment Landscape Gaining Renewed Scientific and Clinical Focus?

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are rare but fatal neurodegenerative disorders characterized by the misfolding of prion proteins, leading to brain damage and rapid cognitive decline. Despite their low prevalence, prion diseases such as Creutzfeldt-Jakob Disease (CJD), variant CJD (vCJD), Fatal Familial Insomnia (FFI), and Kuru have garnered increasing attention from both researchers and regulatory agencies. The lack of curative therapies and the typically rapid disease progression necessitate urgent innovation in diagnostics, therapeutic agents, and supportive care strategies.

Recent advances in molecular biology and prion protein chemistry have revitalized drug discovery programs. Investigations are focusing on small-molecule inhibitors, anti-prion antibodies, and RNA-targeted therapies that can prevent the conversion of normal prion protein (PrP^C) into its pathogenic form (PrP^Sc). Additionally, increased funding from rare disease initiatives and collaborative efforts between academia, government agencies, and biotech companies are accelerating preclinical and early-stage clinical studies. The emergence of humanized mouse models, protein misfolding cyclic amplification (PMCA) techniques, and RT-QuIC assays are further enhancing target validation and therapeutic screening in prion research.

What Treatment Strategies and Research Modalities Are Being Explored Across the Development Pipeline?

The prion disease treatment landscape is largely divided between symptomatic care and experimental disease-modifying therapies. Current standards of care rely on supportive interventions-such as anticonvulsants, antidepressants, and muscle relaxants-to alleviate symptoms, but these do not address the underlying protein misfolding pathology. Experimental treatments are targeting the disease at a molecular level, using approaches such as polyanionic compounds (e.g., pentosan polysulfate), anti-prion monoclonal antibodies, and siRNA molecules to block prion replication or aggregation.

Small-molecule approaches are investigating compounds that bind to prion protein and stabilize its native conformation or disrupt PrP^Sc aggregates. Additionally, drug repurposing efforts have identified candidates such as quinacrine, doxycycline, and flupirtine, although clinical results remain mixed. Immunotherapeutic strategies-including passive immunization using anti-PrP antibodies-have shown promise in animal models but face challenges in crossing the blood-brain barrier. Gene therapy approaches, such as CRISPR-mediated silencing of the PRNP gene, are being explored at the preclinical level, offering a long-term potential route to reduce prion synthesis in high-risk individuals or familial carriers.

How Are Diagnostics, Surveillance, and Regulatory Frameworks Supporting Market Development?

Early and accurate diagnosis remains a significant challenge due to the heterogeneous clinical presentation and rapid disease course of prion disorders. However, innovations in molecular diagnostics are narrowing the detection window. Techniques such as RT-QuIC allow for the amplification and detection of minute amounts of PrP^Sc in cerebrospinal fluid (CSF) and nasal brushings, enabling ante-mortem diagnosis with higher specificity and sensitivity than previously possible. These advances are aiding in patient stratification for clinical trials and are being incorporated into surveillance programs across Europe, North America, and Asia-Pacific.

Regulatory bodies such as the U.S. FDA and the EMA are facilitating rare disease treatment development through orphan drug designations, fast-track reviews, and grant support for clinical studies. The U.K. and Japan have also established TSE reference laboratories and monitoring centers to collect epidemiological data and screen for iatrogenic or zoonotic transmissions. Global collaboration among national surveillance networks-such as EuroCJD and the U.S. National Prion Disease Pathology Surveillance Center-is streamlining data sharing and facilitating multicenter trials. These structural improvements are critical for overcoming the small patient population and diagnostic complexity that have historically hindered clinical research in this domain.

What Factors Are Driving the Growth of the Global Prion Disease Treatment Market?

The growth in the global prion disease treatment market is driven by unmet medical need, increasing translational research, and regulatory incentives for rare neurodegenerative diseases. As demographic aging accelerates the incidence of neurodegenerative disorders, greater awareness and diagnosis of rare variants such as sporadic and familial CJD are expected. Additionally, the re-emergence of zoonotic prion diseases-such as Bovine Spongiform Encephalopathy (BSE) and Chronic Wasting Disease (CWD) in cervids-is renewing interest in the development of prophylactic and therapeutic solutions.

Growing investment in neuroscience R&D, including through initiatives like the NIH’s BRAIN Initiative and Horizon Europe’s rare disease platforms, is strengthening the early-stage innovation pipeline. Pharmaceutical and biotech companies are increasingly targeting niche but high-need markets where market exclusivity and premium pricing are attainable. Enhanced diagnostic capabilities, increased genetic screening, and the rise of precision medicine are improving patient identification and enabling more targeted interventions. Continued convergence of academic, regulatory, and commercial efforts will be critical in translating preclinical promise into viable therapies for one of the most challenging categories of neurodegenerative disease.

SCOPE OF STUDY:

The report analyzes the Prion Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Human Treatment, Animal Treatment); Drug (Antidepressant Drugs, Antipsychotic Agents)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Alector, Inc.
  • Alnylam Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CureVac AG
  • Eli Lilly and Company
  • Genentech (Roche Group)
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Neurotech Pharmaceuticals
  • Novartis AG
  • Orphazyme A/S
  • Prothena Biosciences, Inc.
  • Sage Therapeutics
  • Sangamo Therapeutics, Inc.
  • Teva Pharmaceuticals
  • Tetra Discovery Partners
  • Wave Life Sciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37824

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Prion Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnostic Advancements Propel Demand for Prion Disease Therapeutics
    • Increased Government Funding for Rare Disease Research Expands Scope for Therapeutic Innovation
    • Lack of Effective Treatments Throws the Spotlight on Unmet Clinical Needs in Prion Disorders
    • OEM Collaborations With Academic Research Institutes Accelerate Preclinical Pipeline Development
    • Technological Advancements in Protein Misfolding Assays Enhance Early Diagnosis Capabilities
    • Growth in Companion Diagnostic Tools Strengthens Case for Targeted Therapeutic Development
    • Regulatory Incentives for Orphan Drug Designation Promote Investment in Novel Mechanisms
    • Increased Focus on Neurodegenerative Disease Pathways Fuels Interest in Prion Aggregation Inhibitors
    • Emergence of RNA-Based and Antibody Therapies Drives Hope for Disease-Modifying Interventions
    • Demand for Biomarker-Based Progression Monitoring Supports Clinical Trial Endpoint Validation
    • Expansion of Brain Bank and Tissue Research Infrastructure Enhances Pathology Understanding
    • Rising Incidence of iatrogenic and variant Creutzfeldt-Jakob Disease Creates Public Health Priority
    • Push for Animal Disease Surveillance and Zoonotic Risk Monitoring Strengthens Early Intervention Frameworks
    • Private-Public Research Collaborations Create Opportunities for Translational Funding Support
    • Adoption of AI in Disease Modeling and Drug Repurposing Promotes Rapid Screening of Candidates
    • Patient Advocacy and Support Networks Strengthen Awareness and Accelerate Trial Participation
    • Growth in Academic-Industry Licensing Deals for Prion-Targeted Technologies Fuels Innovation Pipelines
    • Data Sharing Consortia and Global Registries Promote Longitudinal Study of Disease Progression
    • Regulatory Harmonization Across US and EU Encourages Simultaneous Approval Pathways
    • Challenges in Blood and Surgical Transmission Risk Spur Development of Preventive Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prion Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prion Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Human Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Human Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Human Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Animal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Animal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Animal Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antipsychotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antipsychotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antipsychotic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • JAPAN
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • CHINA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • EUROPE
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Prion Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • FRANCE
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • GERMANY
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Prion Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • INDIA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Prion Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Prion Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • AFRICA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!